Sanofi scraps Nurix STAT6 drug just two months after it entered the clinic
Sanofi scraps Nurix STAT6 drug just two months after it entered the clinic
Sanofi scraps Nurix STAT6 drug just two months after it entered the clinic
Key points
اہم نکات
मुख्य बातें
- Sanofi has ended work on a STAT6 degrader licensed from Nurix Therapeutics, just two months after taking the drug, SAR448272, into a first Phase 1 trial for type 2 inflammatory diseases such as eczema and asthma.
- Nurix said Sanofi stopped the trial and terminated the program, wiping out about 455 million dollars in potential milestone payments and royalties tied to the drug.
- Nurix shares fell by roughly a third in after-hours trading.
- Sanofi has ended work on a STAT6 degrader licensed from Nurix Therapeutics, just two months after taking the drug, SAR448272, into a first Phase 1 trial for type 2 inflammatory diseases such as eczema and asthma.
- Nurix said Sanofi stopped the trial and terminated the program, wiping out about 455 million dollars in potential milestone payments and royalties tied to the drug.
- Nurix shares fell by roughly a third in after-hours trading.
- Sanofi has ended work on a STAT6 degrader licensed from Nurix Therapeutics, just two months after taking the drug, SAR448272, into a first Phase 1 trial for type 2 inflammatory diseases such as eczema and asthma.
- Nurix said Sanofi stopped the trial and terminated the program, wiping out about 455 million dollars in potential milestone payments and royalties tied to the drug.
- Nurix shares fell by roughly a third in after-hours trading.
Sanofi has ended work on a STAT6 degrader licensed from Nurix Therapeutics, just two months after taking the drug, SAR448272, into a first Phase 1 trial for type 2 inflammatory diseases such as eczema and asthma. Nurix said Sanofi stopped the trial and terminated the program, wiping out about 455 million dollars in potential milestone payments and royalties tied to the drug. Nurix shares fell by roughly a third in after-hours trading. Analysts said the decision appeared to be about the specific molecule rather than the STAT6 target itself. Nurix said it still holds 1.1 billion dollars in cash, enough to fund operations into the second half of 2029.
Sanofi has ended work on a STAT6 degrader licensed from Nurix Therapeutics, just two months after taking the drug, SAR448272, into a first Phase 1 trial for type 2 inflammatory diseases such as eczema and asthma. Nurix said Sanofi stopped the trial and terminated the program, wiping out about 455 million dollars in potential milestone payments and royalties tied to the drug. Nurix shares fell by roughly a third in after-hours trading. Analysts said the decision appeared to be about the specific molecule rather than the STAT6 target itself. Nurix said it still holds 1.1 billion dollars in cash, enough to fund operations into the second half of 2029.
Sanofi has ended work on a STAT6 degrader licensed from Nurix Therapeutics, just two months after taking the drug, SAR448272, into a first Phase 1 trial for type 2 inflammatory diseases such as eczema and asthma. Nurix said Sanofi stopped the trial and terminated the program, wiping out about 455 million dollars in potential milestone payments and royalties tied to the drug. Nurix shares fell by roughly a third in after-hours trading. Analysts said the decision appeared to be about the specific molecule rather than the STAT6 target itself. Nurix said it still holds 1.1 billion dollars in cash, enough to fund operations into the second half of 2029.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।